Page 13 - Multiple Sclerosis Ms News Today

Former employee/whistleblower to receive $250 million as part of settlement involving three drugs used to treat muscular sclerosis.

Aerobic exercise has the potential to restore function in adults with MS and thalamic atrophy — a patient population at increased risk for progressive physical and cognitive decline.

The top 3 things you should know to start your day.

Ublituximab is superior to teriflunomide in suppressing multiple sclerosis relapses and lesions on MRI, suggest findings from the phase 3 ULTIMATE I and II trials.

New research suggests healthcare spending as an alternative to the "latitude hypothesis" to better explain the higher prevalence of multiple sclerosis found in countries far from the equator.

Certain risk factors can increase the odds of poor physical and mental quality of life decades after a patient receives a multiple sclerosis diagnosis, new research suggests.

Cognitive impairment may be a predictor of physical disability progression and future wheelchair dependence in patients with secondary-progressive multiple sclerosis, new research suggests.

The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated.

COVID rates after vaccination are relatively low and cases mild in patients with multiple sclerosis treated with disease-modifying therapies – but vaccine antibody response is lower with anti-CD20 therapies.

The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.